Melatonin as an effective protector against doxorubicin-induced cardiotoxicity

American Journal of Physiology - Heart and Circulatory Physiology - Tập 283 Số 1 - Trang H254-H263 - 2002
Xuwan Liu1, Zhongyi Chen2, Chu Chang Chua2, Yan-Shan Ma3, George A. Youngberg3, Ronald C. Hamdy2, Balvin H.L. Chua2,1
1Department of Pharmacology
2Cecile Cox Quillen Laboratory of Geriatric Research, and
3Department of Pathology, James H. Quillen School of Medicine, East Tennessee State University and James H. Quillen Veterans Affairs Medical Center, Johnson City, Tennessee 37614

Tóm tắt

The present study was designed to explore the protective effects of melatonin and its analogs, 6-hydroxymelatonin and 8-methoxy-2-propionamidotetralin, on the survival of doxorubicin-treated mice and on doxorubicin-induced cardiac dysfunction, ultrastructural alterations, and apoptosis in mouse hearts. Whereas 60% of the mice treated with doxorubicin (25 mg/kg ip) died in 5 days, almost all the doxorubicin-treated mice survived when melatonin or 6-hydroxymelatonin (10 mg/l) was administered in their drinking water. Perfusion of mouse hearts with 5 μM doxorubicin for 60 min led to a 50% suppression of heart rate × left ventricular developed pressure and a 50% reduction of coronary flow. Exposure of hearts to 1 μM melatonin or 6-hydroxymelatonin reversed doxorubicin-induced cardiac dysfunction. 8-Methoxy-2-propionamidotetralin had no protective effects on animal survival and on in vitro cardiac function. Infusion of melatonin or 6-hydroxymelatonin (2.5 μg/h) significantly attenuated doxorubicin-induced cardiac dysfunction, ultrastructural alterations, and apoptosis in mouse hearts. Neither melatonin nor 6-hydroxymelatonin compromised the antitumor activity of doxorubicin in cultured PC-3 cells. These results suggest that melatonin protect against doxorubicin-induced cardiotoxicity without interfering with its antitumor effect.

Từ khóa


Tài liệu tham khảo

10.1034/j.1600-079X.2001.310104.x

Arola OJ, 2000, Cancer Res, 60, 1789

10.1007/BF02912092

Billingham ME, 1978, Cancer Treat Rep, 62, 865

10.1016/0002-9343(78)90802-1

10.1152/ajpheart.2001.280.5.H2313

Davies KJ, 1986, J Biol Chem, 261, 3060, 10.1016/S0021-9258(17)35746-0

10.1016/S0300-483X(99)00039-6

10.1172/JCI109642

10.1016/S0165-6147(00)88978-6

10.1007/PL00004956

10.1161/01.RES.68.6.1610

10.1126/science.272.5262.731

10.1016/0076-6879(90)86106-6

10.1016/S0149-7634(05)80016-8

Hasinoff BB., 1998, Semin Oncol, 25, 3

10.1007/BF00686629

10.1074/jbc.271.21.12610

10.1172/JCI119672

10.1016/0305-7372(91)90002-H

10.1074/jbc.M003890200

10.1111/j.1749-6632.1999.tb09233.x

10.1016/S0959-8049(99)00159-8

Monti E, 1995, Anticancer Res, 15, 193

10.1007/s002800050888

10.1096/fasebj.4.13.2210154

10.1097/00005344-198609000-00026

10.1016/0024-3205(94)00666-0

10.1023/A:1005856605726

10.1111/j.1476-5381.1996.tb15326.x

Rajagopalan S, 1988, Cancer Res, 48, 4766

10.1159/000109516

10.1016/S0024-3205(97)00030-1

10.1159/000014636

Samelis GF, 1998, Anticancer Res, 18, 3305

10.1016/0006-2952(93)90514-W

10.1161/01.CIR.91.1.10

10.1161/01.CIR.89.6.2829

10.1093/jnci/82.13.1107

10.1177/030089160008600210

Wang GW, 2001, J Pharmacol Exp Ther, 298, 461

Weinstein DM, 2000, J Pharmacol Exp Ther, 294, 396

10.1006/abbi.1998.1011

10.1172/JCI118909

10.1161/01.CIR.100.20.2100

Thông tin
Thông tin xuất bản

American Journal of Physiology - Heart and Circulatory Physiology

Tập 283 Số 1

H254-H263

Thông tin tác giả